Myriad Genetics has used broad gene patents to operate
a monopoly over testing for the two BRCA genes, which when mutated can cause inherited forms of breast cancer.
It has used broad gene patents to operate
a monopoly over testing for the two BRCA genes, which when mutated can cause inherited forms of breast cancer.
Not exact matches
This challenge arose from complaints made initially by breast cancer patients who objected to Myriad's
monopoly control
over the
testing and interpretation of risks associated with these cancer genes.
Myriad has used sequences on the BRCA1 and BRCA2 genes to develop a diagnostic
test over which it or its international representatives have held a potentially lucrative
monopoly.